Join Pharmaron from October 11 – 14, 2026 at the 27th ISSX North America

Pharmaron will be exhibiting at the 27th North American International Society for the Study of Xenobiotics (ISSX) Meeting at the Hilton San Francisco Union Square in San Francisco, California, USA from October 11–14, 2026.

Pharmaron supports programmes from early discovery through to clinical development, bringing together expertise in radiolabelling and integrated ADME studies to give a clear understanding of how compounds behave. From early screening to regulatory toxicology, our seamless end-to-end approach helps move projects forward with confidence. We’re at Booth #310 at ISSX to connect with the DMPK community, share our research and expertise, and engage with the latest innovations shaping the future of drug discovery.

If you would like to schedule a meeting with our team, click the link below. We’d love to discuss your requirements and challenges.

The Pharmaron attending team includes:

Barry Jones, Chief Scientist, Global DMPK, in vitro DMPK
Danxi Li, Vice President, ADMET Head
Wei Li, Director, ADMET
Tom Kralj, Senior Bioanalytical Scientist I, LC-MS Bioanalysis
Connie Sun, Global Head of BD, Small Molecule
Jennifer Liu, Director, Business Development
Guru Valicherla, Senior Scientist II
Igor Mezine, Principal Research Fellow
Rakhsar Shabir, Senior Study Manager, Metabolism
Claire Repellin, Senior Manager, Account Management
Jennifer Milanovich, Executive Director, Business Development, Radiolabelled Sciences
Libo Xu, Senior Director, Business Development, US Lab Services
Dave Nuel, Director, Business Development, US Labs Services
Neha Yevalekar, Business Development, Biologics

Our ISSX North America 2026 Schedule

Exhibit Booth # 310

Exhibit Hall & Poster Presentation Hours

Monday, October 12 – 9:30 a.m. – 7:30 p.m.
Tuesday, October 13 – 9:30 a.m. – 7:30 p.m.
Wednesday, October 14 – 9:30 a.m. – 2:30 p.m

Schedule a Meeting Below

Barry Jones
Chief Scientist
Global DMPK

Danxi Li
Vice President
ADMET Head

Wei Li
Director
ADMET

Thomas Kralj
Sr. Bioanalytical Scientist I

Connie Sun
Senior Vice President
Business and Corporate Development

Scientist wearing glasses and a striped shirt with a name badge, framed in an oval border against a light gray background. — Guru Valicherla
Senior Scientist II
Regulatory In Vitro ADME

Male scientist with short brown hair wearing a light blue collared shirt, smiling slightly, framed in a blue oval. — Igor Mezine
Principal Research Fellow

Rakhsar Shabir, Pharmaron professional, in an oval frame with a navy border on a grey background — Rakhsar Shabir
Senior Study Manager
Metabolism

Claire Repellin
Senior Manager
Account Management

Scientist with glasses wearing a black blazer and yellow floral blouse, framed in an oval with a blue border. — Libo Xu
Senior Director
Business Development

Neha Yevalekar
Directof of Business Development
Discovery Biologics

Talks and Posters

Featured Scientific Presentation

Streamlining ADC Bioanalysis: Workflow for the Simultaneous Quantitation of Free Payload, Intact ADC, and Total Antibody Using a Single-Sample

Presenter: Tom Kralj
Date/Time/Location: to be confirmed
You will learn about:
- Exploring bioanalytical approaches for quantifying and characterising complex ADC therapeutics.
- Addressing analytical challenges associated with increasingly sophisticated bioconjugate modalities.
- Supporting the development of next-generation ADCs through robust and fit-for-purpose bioanalytical strategies.

Roundtable Discussion

Capitalizing on External ADME Capabilities in Drug Discovery and Development

Presented by: Barry Jones
Date/Time: Monday, October 12, 2026, 5:15 PM – 6:15 PM
You will learn about:
- Collaboration fuels superior science. Many sponsors are embracing external ADME partners that provide scientific expertise, innovation, and decision support – beyond merely delivering data.
- Consolidation allows for streamlining. Integrating numerous ADME disciplines under the umbrella of one CRO partner simplifies project management by limiting handoffs and speeding up crucial development decisions.
- Subject matter expertise speeds success. Experienced ADME scientists, cutting-edge technology, and worldwide capabilities allow sponsors to overcome the challenges of complex drug modalities and advance programs with confidence

Posters

Development of a High-Throughput In Vitro Screening Platform for Oral Bioavailability Prediction of Peptides

Presented by: Danxi Li
Date/Time/Location: Monday, October 12, 2026, 1:30 PM – 2:15 PM | Poster #P3
You will learn about:
- Exploring integrated approaches to predict oral peptide absorption by evaluating mucus penetration and epithelial permeability barriers.
- Developing high-throughput screening strategies to support candidate selection and improve confidence in oral peptide development.
- Advancing translational methodologies that help bridge the gap between in vitro screening data and in vivo performance.

High-Throughput Multiparametric Hepatotoxicity Profiling for Translational Prediction of Clinical Drug-Induced Liver Injury

Presented by: Wei Li
Date/Time/Location: Tuesday, October 13, 2026, 12:45 PM – 1:30 PM | Poster #P96
You will learn about:
- Applying advanced 2D and 3D human liver models to improve early assessment of hepatotoxicity risk.
- Investigating mechanistic signatures associated with drug-induced liver injury (DILI).
- Supporting more predictive and translational approaches to safety evaluation during drug development.

Application of the HepatoPac® Model for Determination of In Vitro Intrinsic Clearance and In Vitro-In Vivo Correlation

Presented by: Guru Raghavendra Valicherla
Date/Time/Location: Monday, October 12, 2026, 2:15 PM – 3:00 PM | Poster #P12
You will learn about:
- Evaluating advanced hepatic co-culture systems for prediction of human hepatic clearance.
- Improving in vitro-in vivo correlation (IVIVC) across low-, moderate-, and high-clearance compounds.
- Demonstrating the value of human-relevant liver models for translational DMPK decision-making.

Comparative Metabolite Profiling in HepatoPac® and Human Hepatocyte Models

Presented by: Igor Mezine
Date/Time/Location: Monday, October 12, 2026, 2:15 PM – 3:00 PM | Poster #P26
You will learn about:
- Comparing metabolite formation across long-term HepatoPac® cultures and conventional hepatocyte suspension systems.
- Investigating the impact of hepatic model selection on metabolite identification and characterisation.
- Generating insights to support human-relevant metabolism studies and regulatory submissions.

Inter-Laboratory Reproducibility of Midazolam Oral Bioavailability Assessment Using Gut/Liver Microphysiological Systems and Mechanistic Modelling

Presented by: Barry Jones
Date/Time/Location: Tuesday, October 13, 2026, 12:45 PM – 1:30 PM | Poster #P86
You will learn about:
- Assessing the reproducibility of oral bioavailability predictions generated using gut/liver microphysiological systems.
- Combining advanced in vitro models with mechanistic modelling approaches to improve translational relevance.
- Evaluating the potential of human-relevant systems to support prediction of first-pass metabolism and oral exposure.

Impact of Experimental Variables on Conclusions from Caco-2 Permeability Classification in the Context of the ICH M9 Guidance on the BCS

Presented by: Rachana Patel & Blair Meiezeiewski
Date/Time/Location: Tuesday, October 13, 2026, 12:00 PM – 12:45 PM | Poster #P93
You will learn about:
- Investigating factors that influence permeability assessment and Biopharmaceutics Classification System (BCS) designation.
- Evaluating assay robustness and reproducibility within validated Caco-2 models.
- Providing insights relevant to permeability classification and BCS-based biowaiver strategies under ICH M9 guidance.

ADME: 14C-Exicorilant Following Oral Administration to Rats and Mini-Pigs

Presented by: Rakhsar Shabir
Date/Time/Location: Wednesday, October 14, 2026, 12:00 PM – 12:45 PM | Poster #P123
You will learn about:
- Characterising absorption, distribution, metabolism and excretion pathways using radiolabelled ADME studies.
- Investigating metabolite profiles, tissue distribution, and routes of elimination across preclinical species.
- Generating comprehensive disposition data to support informed development decisions.

Establishment of a Primary Human Hepatocytes-Derived Organoid Platform for Drug-Induced Liver Injury Screening

Presented by: Danxi Li
Tuesday, October 13, 2026, 12:00 PM – 12:45 PM | Poster #P97
You will learn about:
- PHH-derived liver organoids can be expanded long-term while maintaining important liver functions, creating a more reliable model for drug safety testing.
- The organoid platform successfully identified drug-induced liver injury risk, achieving over 70% predictive accuracy and more than 80% sensitivity.
- By combining multiple readouts, the model can detect liver toxicity and provide insight into the mechanisms driving liver damage.

About the ISSX North America Meeting

The 27th North American ISSX Meeting will focus on deepening the understanding of emerging technologies and innovations in drug metabolism, pharmacokinetics, and drug transport research. The event will feature in-depth short courses addressing microphysiological systems, in vitro and in vivo extrapolation, DMPK characterization of biologics, emerging insights into extrahepatic metabolism, and state-of-the-art exhibits, offering attendees both foundational knowledge and forward-looking perspectives on the future of DMPK.

For more information and event registration details, please visit the ISSX website.

Complete this form to Request a Meeting

Meeting Request Form

Meeting requests during a conference or event

Name(Required)

First Last

Company Name(Required)

Job Title

Email(Required)

What services would you like to discuss?(Required)

What time of the day works best for you (morning, afternoon, or evening)?(Required)

Which day or days of the conference are best for you to meet? If you need a specific date and time window, make a note here.

By completing and submitting this form, you acknowledge that you have read and understood our Privacy Policy, and you consent to the collection and processing of your personal data by Pharmaron for the purpose of responding to your inquiry. You also agree to be contacted by Pharmaron regarding relevant services and updates. You may withdraw your consent at any time.